Determining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysis
Autor/a
Zozaya, Néboa
Martínez-Galdeano, Lucía
Alcala, Bleric
Armario-Hita, Jose Carlos
Carmona, Concepción
Carrascosa, Jose Manuel
Herranz, Pedro
Lamas, María Jesús
Trapero Bertran, Marta
Hidalgo-Vega, Álvaro
Fecha de publicación
2018ISSN
1173-8804
Resumen
Background and Objective: Multi-criteria decision analysis (MCDA) is a tool that systematically considers multiple factors relevant to health decision-making. The aim of this study was to use an MCDA to assess the value of dupilumab for severe atopic dermatitis compared with secukinumab for moderate to severe plaque psoriasis in Spain. Method: Following the EVIDEM (Evidence and Value: Impact on DEcision Making) methodology, the estimated value of both interventions was obtained by means of an additive linear model that combined the individual weighting (between 1 and 5) of each criterion with the individual scoring of each intervention in each criterion. Dupilumab was evaluated against placebo, while secukinumab was evaluated against placebo, etanercept and ustekinumab. A retest was performed to assess the reproducibility of weights, scores and value estimates. Results: The overall MCDA value estimate for dupilumab versus placebo was 0.51 ± 0.14. This value was higher than those obtained for secukinumab: 0.48 ± 0.15 versus placebo, 0.45 ± 0.15 versus etanercept and 0.39 ± 0.18 versus ustekinumab. The highest-value contribution was reported by the patients’ group, followed by the clinical professionals and the decision makers. A fundamental element that explained the difference in the scoring between pathologies was the availability of therapeutic alternatives. The retest confirmed the consistency and replicability of the analysis. Conclusions: Under this methodology, and assuming similar economic costs per patient for both treatments, the results indicated that the overall value estimated of dupilumab for severe atopic dermatitis was similar to, or slightly higher than, that of secukinumab for moderate to severe plaque psoriasis.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
English
Materias (CDU)
61 - Medicina
616.5 - Piel. Dermatología clínica
Palabras clave
Medicines
Fàrmacs
Malalties inflamatòries
Pell
Fàrmacs biològics
Medicinas
Fármacos
Enfermedades inflamatorias
Piel
Fármacos biológicos
Medicines
Drugs
Inflammatory diseases
Pell
Biological drugs
Páginas
11
Publicado por
Springer Nature
Colección
32;
Publicado en
BioDrugs
Citación
Zozaya, Néboa; Martínez-Galdeano, Lucía; Alcala, Bleric [et al.]. Determining the value of two biologic drugs for chronic inflammatory skin diseases: results of a multi-criteria decision analysis. BioDrugs, 2018, 32, p. 281-291. Disponible en: <https://link.springer.com/article/10.1007/s40259-018-0284-3>. Fecha de acceso: 28 jun. 2021. DOI: 10.1007/s40259-018-0284-3
Este ítem aparece en la(s) siguiente(s) colección(ones)
- Ciències de la Salut [740]
Derechos
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by-nc/4.0/